- Home
- QLYS vs OGN Comparison
QLYS vs OGN Comparison
Compare QLYS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLYS
- OGN
- Stock Information
- Founded
- QLYS 1999
- OGN 1923
- Country
- QLYS United States
- OGN United States
- Employees
- QLYS N/A
- OGN N/A
- Industry
- QLYS Computer Software: Prepackaged Software
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- QLYS Technology
- OGN Health Care
- Exchange
- QLYS Nasdaq
- OGN Nasdaq
- Market Cap
- QLYS 5.0B
- OGN 4.0B
- IPO Year
- QLYS 2012
- OGN N/A
- Fundamental
- Price
- QLYS $136.20
- OGN $15.48
- Analyst Decision
- QLYS Hold
- OGN Hold
- Analyst Count
- QLYS 17
- OGN 5
- Target Price
- QLYS $146.57
- OGN $20.80
- AVG Volume (30 Days)
- QLYS 374.7K
- OGN 2.9M
- Earning Date
- QLYS 02-06-2025
- OGN 02-13-2025
- Dividend Yield
- QLYS N/A
- OGN 7.24%
- EPS Growth
- QLYS 15.38
- OGN N/A
- EPS
- QLYS 4.65
- OGN 3.33
- Revenue
- QLYS $607,571,000.00
- OGN $6,403,000,000.00
- Revenue This Year
- QLYS $9.24
- OGN $2.06
- Revenue Next Year
- QLYS $7.19
- OGN $1.85
- P/E Ratio
- QLYS $29.29
- OGN $4.65
- Revenue Growth
- QLYS 9.58
- OGN 2.24
- 52 Week Low
- QLYS $119.17
- OGN $13.87
- 52 Week High
- QLYS $174.31
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- QLYS 42.77
- OGN 50.46
- Support Level
- QLYS $135.20
- OGN $15.26
- Resistance Level
- QLYS $147.86
- OGN $15.90
- Average True Range (ATR)
- QLYS 4.97
- OGN 0.63
- MACD
- QLYS -0.12
- OGN 0.04
- Stochastic Oscillator
- QLYS 22.16
- OGN 35.19
About QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.